Description

(33R)-N1-[4-(Amidinoamino)Butyl]Bleomycinamide is a chemically modified derivative of the bleomycin family of glycopeptide antibiotics, representing a key intermediate in advanced pharmaceutical research and development. This compound is valued for its role in the synthesis of novel therapeutic agents targeting specific cellular mechanisms. It is primarily utilized by research institutions and pharmaceutical companies engaged in the development of next-generation oncology treatments and antimicrobial therapies. The precise structural modification offers a critical building block for creating molecules with enhanced potency and selectivity.

Application

• Pharmaceutical Intermediate: Serves as a critical precursor in the synthesis of novel bleomycin analogs for cancer chemotherapy research.
• Oncology Drug Discovery: Used in the development of targeted anti-tumor agents that cleave DNA, focusing on improving therapeutic index and reducing side effects.
• Antimicrobial Research: Investigated for creating new antibiotic candidates to combat resistant bacterial strains.
• Biochemical Tool Compound: Employed in mechanistic studies to understand the interaction of bleomycin-type molecules with nucleic acids.
• Process Chemistry & Scale-up: Utilized in optimizing synthetic routes for the production of clinical trial materials.
• Academic Research: A key material for universities and institutes studying the structure-activity relationships of complex glycopeptides.

Basic Information

Product Name	(33R)-N1-[4-(Amidinoamino)Butyl]Bleomycinamide
CAS No.	62624-78-6
Molecular Formula	Contact for details
Molecular Weight	Contact for details
Synonyms	Bleomycinamide, N1-[4-(Amidinoamino)butyl]-, (33R)-; (33R)-N1-(4-Guanidinobutyl)bleomycinamide; Bleomycin A2 derivative; N1-(4-Guanidinobutyl)bleomycinamide; BLM derivative; Antibiotic derivative 62624-78-6; Guanidinobutylbleomycinamide
EINECS	Contact for details

Quality Control

Our (33R)-N1-[4-(Amidinoamino)Butyl]Bleomycinamide is produced under strict quality management systems to ensure batch-to-batch consistency and high purity for research applications. Each lot is accompanied by a comprehensive Certificate of Analysis (COA) detailing identity, purity, and impurity profiles. We adhere to cGMP guidelines where applicable for pharmaceutical intermediates, and our analytical methods, including HPLC and spectroscopy, are validated to provide reliable data. Certificates of Analysis (COA) are available upon request.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). Due to its hygroscopic (moisture-sensitive) nature, the container must be kept tightly sealed in a dry environment to prevent degradation. For long-term storage, consider desiccants or inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Assay (HPLC)	≥ 95.0%
Water Content (KF)	≤ 5.0%
Related Substances (HPLC)	Total impurities ≤ 3.0%
Single Unknown Impurity	≤ 1.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.